Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Intercept Pharmaceuticals, Inc. ICPT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
62/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$22.11
+16.4%

Intercept Pharmaceuticals, Inc. (ICPT) is a Biotechnology company in the Healthcare sector, currently trading at $19.00. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ICPT = $22 (+16.4% upside).

Financials: revenue is $286M, +6.3%/yr average growth. Net income is $115M, growing at +83.9%/yr. Net profit margin is 40.3% (strong). Gross margin is 99.7% (+1.4 pp trend).

Balance sheet: total debt is $333M against $93M equity (Debt-to-Equity (D/E) ratio 3.57, leveraged). Current ratio is 2.35 (strong liquidity). Debt-to-assets is 60.1%. Total assets: $554M.

Analyst outlook: 16 / 40 analysts rate ICPT as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 86/100 (Pass), Growth 83/100 (Pass), Past 25/100 (Fail), Health 33/100 (Fail), Moat 60/100 (Partial), Future 46/100 (Partial), Income 100/100 (Pass).

$22.11
▲ 16.37% Upside
Average Price Target
Based on 40 Wall Street analysts offering 12-month price targets for Intercept Pharmaceuticals, Inc., the average price target is $22.11, with a high forecast of $44.00, and a low forecast of $10.00.
Highest Price Target
$44.00
Average Price Target
$22.11
Lowest Price Target
$10.00

ICPT SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 86/100
Valuation — P/E, PEG, Forward PEG
GROWTH 83/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 60/100
Gross margin is + market cap
FUTURE 46/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ICPT

✓
VALUE Pass
86/100
ICPT trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $22, implying +15.8% from the current price $19. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
83/100
ICPT: +6.3%/yr revenue is, +83.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
ICPT: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✗
HEALTH Fail
33/100
Balance sheet ICPT: Debt-to-Equity (D/E) ratio 3.57 (leveraged), Current ratio is 2.35 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
60/100
ICPT: Gross margin is 99.7% (+1.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 60/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
46/100
Analyst outlook: 16 / 40 analysts rate ICPT as buy (40%). Analyst consensus target is $22 (+15.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✓
INCOME Pass
100/100
ICPT: Net profit margin is 40.3%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range8.82-21.86
Volume3.91M
Avg Volume (30D)2.05M
Market Cap$794.69M
Beta (1Y)0.88
Share Statistics
EPS (TTM)3.41
Shares Outstanding$33.82M
IPO Date2012-10-11
Employees341
CEOJerome B. Durso
Financial Highlights & Ratios
Revenue (TTM)$285.71M
Gross Profit$284.73M
EBITDA$-61.7M
Net Income$115.17M
Operating Income$-68.22M
Total Cash$490.91M
Total Debt$332.67M
Net Debt$282.16M
Total Assets$553.71M
Price / Earnings (P/E)5.6
Price / Sales (P/S)2.78
Analyst Forecast
1Y Price Target$19.00
Target High$44.00
Target Low$10.00
Upside0.0%
Rating ConsensusHold
Analysts Covering40
Buy 40% Hold 48% Sell 13%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS45845P1084

Price Chart

Track all markets on TradingView
ICPT
Intercept Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
8.82 52WK RANGE 21.86

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 PTCT
PTCT
PTC Therapeutics, Inc.
$73.01
+3.68%
 TGTX
TGTX
TG Therapeutics, Inc.
$34.56
+2.28%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message